Aducanumab Removes Superficial Cortical Amyloid but Associates with Local Vascular Injury and ARIA: Clinicopathological Evidence from a Retrospective Case–Control Study
Autopsy of aducanumab-treated Alzheimer’s cases shows preferential clearance of superficial layer I amyloid, PET Centiloid reductions, and ARIA-associated microvascular pathology, implicating perivascular amyloid removal and vessel injury as mechanisms that inform monitoring and therapy design.